A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer | Zendy

Sotaro Sadahiro | Zendy; Toshiyuki Suzuki | Zendy; Akira Tanaka | Zendy; Kazutake Okada | Zendy; Gota Saito | Zendy; Akemi Kamijo | Zendy

Open Access

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Author(s) -

Sotaro Sadahiro,

Toshiyuki Suzuki,

Akira Tanaka,

Kazutake Okada,

Gota Saito,

Akemi Kamijo

Publication year - 2015

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000369976

Subject(s) - irinotecan , medicine , bevacizumab , neutropenia , colorectal cancer , chemotherapy , gastroenterology , leukopenia , phases of clinical research , cancer

Protracted low-dose infusion of irinotecan has been suggested to enhance antitumor activity. A phase II study was conducted to evaluate the safety and efficacy of oral S-1 combined with 24-hour infusion of irinotecan and intravenous bevacizumab for metastatic colorectal cancer (MCRC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research